Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma.

ABSTRACT:

Background

Combinations of drugs can improve the efficacy of cancer treatment, enable the reduction of side effects and the occurrence of acquired drug resistance.

Methods

We approached this challenge mathematically by using the validated technology called the Therapeutically Guided Multidrug Optimization (TGMO) method. In a set of genetically distinct human renal cell carcinoma (RCC) cell lines, either treated chronically with sunitinib (-ST) or sunitinib-naive, we identified cell line-specific low-dose-optimised drug combinations (ODC).

Results

Six cell-type-specific low-dose drug combinations for three sunitinib-naive as well as three sunitinib pre-treated cells were established. These ODCs effectively inhibited the RCC cell metabolic activity while being ineffecti

SUBMITTER: Rausch M 

PROVIDER: S-EPMC7435198 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature